DOCSLIB.ORG

Understanding Amenorrhea and PCOS None

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Understanding Amenorrhea and PCOS None UCSF Essentials of Primary Care August 12, 2016 Squaw Creek, CA Disclosure • Understanding Amenorrhea and PCOS None Michael Policar, MD, MPH Professor of Ob, Gyn, and Repro Sciences UCSF School of Medicine policarm@obgyn.ucsf.edu Amenorrhea: Definitions • Primary Amenorrhea – Absence of menarche by • 16 yo with sexual development – ASRM: 15 yo or > 5 years after breasts develop • 14 yo without sexual development • Secondary Amenorrhea (aka: absent menstrual bleeding) – No vaginal bleeding for at least • Three cycle lengths OR six months – Oligomenorrhea with < 9 menses/ year (ASRM,2008) ASRM Fertil Steril 2008;90:S219–25 ASRM: American Society of Reproductive Medicine 1 Presentation Approach to Amenorrhea Reproductive Hormonal Axis HYPOTHALAMUS Hypothalamic • Most common diagnoses early in workup GnRH Amenorrhea • Minimize potentially unnecessary tests and office visits • Separate evaluation schemes for ANTERIOR PITUITARY Pituitary – Spontaneous secondary amenorrhea FSH Amenorrhea – Post-surgical amenorrhea LH – Primary amenorrhea (not today) OVARY Ovarian – Progestin-induced failure to withdraw Estradiol (E 2 ) Failure Progesterone (P) ENDOMETRIUM Outflow Failure 2o Amenorrhea: Amenorrhea: Causes Hypothalamic Amenorrhea • Hypothalamic amenorrhea • • Pituitary amenorrhea Athlete's amenorrhea – • Ovarian failure Critical ratio of muscle to body fat exceeded – Despite exercise, risk osteoporosis (and fracture) • Outflow tract failure • Female athlete triad : disordered eating, amenorrhea, • Anovulatory amenorrhea and osteoporosis • Pregnancy induced amenorrhea – Preoccupation with food and weight, frequent bathroom use during and after meals, laxative use, brittle hair or nails, dental cavities 2 o The Female Athlete Triad 2 Amenorrhea: 2014 Female Athlete Triad Coalition Consensus Statement Clin J Sport Med 2014; 24(2): 96-119 Hypothalamic Amenorrhea • Medical condition often observed in physically active girls and women, and involves 3 components • Anorexia nervosa – Low energy availability + disordered eating • Chronic stress – Menstrual dysfunction • Post-hormonal suppression – Low bone mineral density – Resolves within 3 months of method discontinuation • Early intervention is essential to prevent progression to serious endpoints that include – Clinical eating disorders – Amenorrhea – Osteoporosis o 2 Amenorrhea: 2o Amenorrhea: Pituitary Amenorrhea Ovarian Failure • Hyperprolactinemia – Prolactinoma (prolactin-secreting adenoma) • > 40 years old: True menopause – Drugs, esp antipsychotics • < 40 years old: Premature menopause – Primary hypothyroidism – Premature ovarian failure • Destructive pituitary lesions •Autoimmune; follicles present – Tumors, tuberculosis – Resistant ovary syndrome – Sheehan's syndrome •Non-autoimmune; follicles sparse • Pituitary atrophy after post-partum hemorrhage – Gonadal dysgenesis (mosaic or Fragile X) • Hypothyroid sxs, difficulty lactating, loss of pubic or underarm hair, low BP, fatigue, weight loss 3 2o Amenorrhea: Outflow Tract Failure Anovulatory Amenorrhea • • Cervical Stenosis Compartments intact, but dyssynchronous • – Normal (or high) E 2 levels Occurs after TAB, cryotherapy, cone, or LEEP • – Will have progestin withdrawal bleeding because of Blockage of internal os with blood accumulation estrogen-induced endometrial priming – Cyclic premenstrual sxs with uterine cramping • Causes • Asherman's Syndrome – Hyperandrogenic anovulation • – Endometrial ablation (TAB or curettage) and uterine PCOS, adult onset CAH infection, leads to intrauterine synechiae – Hypothalamic anovulation : stress, wt. loss – – Cyclic premenstrual symptoms, but no cramps Hyperprolactinemia Secondary Amenorrhea Secondary Amenorrhea: The “Big Four” Conditions ASRM, 2008 Hypothalamic Pituitary Ovarian Outflow Anovulatory Amenorrhea Amenorrhea Failure Failure Amenorrhea Athlete’s am. Prolactinoma Menopause Cervical PCOS 1. PCOS 66% Stress HypoT 4 Premat OF stenosis HyperPRL Anorexia Drugs OIS Asherman’s Stress 2. Hypothalamic amenorrhea nervosa Pit tumors Mosaic syndrome 3. Hyperprolactinemia 13% Sheehans syn E: low E: low E: low E: normal E: normal 4. Ovarian failure 12% FSH: low FSH: low FSH: high FSH:normal LH > FSH Outflow tract 7% Other (CAH, ovarian tumor) 2% 4 Hx, PE, Fritz, Speroff: Spontaneous Hx, PE, ASRM 2008: Spontaneous o o Preg test 2 Amenorrhea Preg test 2 Amenorrhea Preg test NEG Preg test NEG Preg test POS TSH, PRL, FSH,E 2 Preg test POS MPA x10d PRL , TSH, FSH Pregnant Pregnant • Incr TSH •E2, FSH normal • E2 low HyperPRL Incr TSH Incr FSH Normal, low FSH •Location •HyperPRLHyperPRL •Location • W/D Bleed + • NO W/D Bleed Ovarian •GA Dating •GA Dating Evaluate, treat Evaluate, treat Anovulation/ Failure PCOS Incr FSH Low FSH Anovulation/ Hypothal/pit Ovarian Hypothal/pit PCOS Failure Failure Failure If androgen- MRI if unexplained MRI if unexplained ization Amenorrhea: Clinical Symptoms Amenorrhea: Clinical Symptoms Symptom Suggestive of Symptom Suggestive of Pregnancy symptoms • Pregnancy Medications • Anovulation • Missed SAB • Hypothalamic amenorrhea Galactorrhea • Hyperprolactinemia Athletics, weight loss • Hypothalamic amenorrhea Headache • Hypothalamic, pituitary dz Hot flashes • Ovarian, central failure Visual changes • Pituitary tumor Cervical or uterine • Cervical stenosis surgery • Asherman's syndrome Hirsuitism, acne • Chronic anovulation/PCOS Cyclic premenstrual • Cervical stenosis • Psychological stress Anovulation symptoms • Asherman's syndrome • Hypothalamic amenorrhea 5 o Amenorrhea: Physical Examination 2 Amenorrhea: Visit 1 • History, physical exam Organ Signs Cause • Highly sensitive urine pregnancy test Skin • Hirsuitism • PCOS • Findings • Acne – Galactorrhea on hx, PE: galactorrhea W/U Breasts • Galactorrhea • ↑ prolacn – Pregnancy test result: Abdomen • Uterus enlarged • Pregnancy •Positive: DX=PREGNANCY ; locate, date Cervix • Pinpoint os • Cervical stenosis •Neg, unprotected sex: Use BC, repeat 2 wk Uterus • Enlargement • Pregnancy •Neg, protected or no sex: proceed t o lab o Visit 2 2o Amenorrhea: Visit 1 2 Amenorrhea: • • Order lab tests Review lab results – – Prolactin, TSH level; not thyroid function tests PRL elevated: hyperprolactinemia evaluation – o – FSH, Estradiol (E ) level; not LH level TSH elevated: 1 hypothyroidism evaluation 2 – – If signs of virilization: total testosterone, DHEAS Testosterone elevated: evaluate ovarian tumor – • Progestin challenge (if performed) DHEAS elevated: evaluate for adrenal tumor • – MPA 10 mg PO QD x 7days OR Review P challenge outcome and lab test results – – Micronized progesterone 400 mg x10d DX= ANOVULATORY AMENORRHEA if… – • Schedule F/U visit 3 weeks FSH and E 2 levels are normal – Progestin withdrawal bleed occurred 6 Anovulatory Amenorrhea 2o Amenorrhea: Visit 2 • Work up not necessary, unless virilization • – If PCOS, check lipids and fasting +2 o PGL glucose levels FSH >20 IU/L, low E 2: DX = OVARIAN DISORDER – • Management > 40 years old: Menopause – Desire contraception – < 40 years old: Premature menopause • Cycle on OC's • Karyotype: if < 30: gonadectomy if Y ch’some – Desire pregnancy • Autoimmune POF: screen with TSH, anti-thyroid • Induce ovulation: clomiphene or letrazole antibodies, FBG, electrolytes – Neither : cycle bleeding, prevent hyperplasia • Ovarian biopsy not indicated • MPA or microP x 10-14d every 1-2 months – If pregnancy is desired, refer for ART (ovum donation) •LN-IUS (Mirena) Post-surgical o 2 Amenorrhea: Visit 2 Hx, PE, Preg test 2o Amenorrhea Preg test POS Preg test NEG • Low FSH (< 5 IU/L) , low E 2 • Pregnant • DX=HYPOTHALAMIC or PITUITARY DISORDER Molimena • + Molimena Cramps – If explained by athletics, anorexia, poor nutrition, or stress, • • NO cramps Location no further evaluation needed • Dilate cervix MPA x10d •GA Dating – If unexplained, or CNS symptoms, exclude pituitary tumor Bleed NO Bleed Bleed NO Bleed • Anovulation EE x 30d “Pituitary MRI” or head CT with contrast MPA x10d – Provide estrogen replacement: low dose OC Cervical Stenosis Bleed NO Bleed – Pregnancy desired: gain weight or induce ovulation with FSH High Nml, low HMG or pulsatile GnRH Ovarian Hypothal/pit Ashermans Failure Failure Syndrome 7 Which feature is a clinical criteria for the PCOS: Overlaping Syndromes diagnosis of PCOS? 46% PCOS Insulin Hyper- A. Obesity 44% B. Hyperinsulinemia Resistance Androgenism C. Oligo-anovulation PCOS D. Glucose intolerance E. All of the above 6% * Hyperandrogenism 2% 2% Chronic (clinical or biochemical) Anovulation y a e * Chronic oligo-anovulation i t e s i o n n c v e e m i t a o b n r b O u l a a o l e s u l i o v h e i n i n t f t * Exclusion of other disorders e e r o - a n s l l o y p g o A H O l i l u c G [ PAO on ultrasound in Rotterdam criteria set] PCOS Diagnostic Criteria PCOS: Chronic Oligo-Anovulation • Menstrual irregularity Diagnostic NIH Rotterdam AE-PCOS – feature 1990 2002 2006 Amenorrhea, oligomenorrhea Any 2 of 3 – Variable cycle length Androgens Elevated Elevated Elevated – DUB (dysfunctional uterine bleeding) Periods Irregular, fewer Irregular Irregular • Absence of molimenal symptoms than 8 per year OR • Prior need for ovulation induction Ovarian Not included in Polycystic Polycystic • No ovulation can be documented with morphology on NIH criteria morphology morphology – ultrasonography Ovulation prediction kit – Basal body temperature measurement – AE-PCOS: Androgen Excess and PCO Society Luteal phase progesterone level 8 PCOS: Hyperandrogenism Polycystic Appearing Ovaries (PAO) • A functional result of local ovarian hyperandrogenism… • Skin manifestations
Load more

Recommended publications
  • Non Hormonal Management of Menstrual Cylce Irregularities
    Journal of Gynecology and Women’s Health ISSN 2474-7602 Review Article J Gynecol Women’s Health Volume 11 Issue 4 - September 2018 Copyright © All rights are reserved by Arif A Faruqui DOI: 10.19080/JGWH.2018.11.555818 Non Hormonal Management of Menstrual Cylce Irregularities Arif A Faruqui* Department of Pharmacology, Clinical Pharmacologist, A 504, Rizvi Mahal, India Submission: August 16, 2018; Published: September 07, 2018 *Corresponding author: Email: Arif A Faruqui, Department of Pharmacology, A 504, Rizvi Mahal Opp. K.B. Bhabha Hospital, Waterfield road Bandra, India, Abstract of bleedingEach month patterns, the endometriumfor example, amenorrhea, becomes inflamed, menorrhagia and the or luminalpolymenorrhea; portion ovarianis shed dysfunctionduring menstruation. for example, Aberrations anovulation in menstrualand luteal physiology can lead to common gynecological conditions, such as heavy or prolonged bleeding. Menstrual dysfunction is defined in terms pathologic process or may predispose a woman to the development of chronic disease. For example, metrorrhagia predisposes to anemia, anddeficiency; the irregular painful menstrual menstruation cycles and associated premenstrual with PCOS syndrome. (see PCOS) Certain can characteristics predispose a woman of menstruation to infertility, can diabetes be a reflection and consequently, of an underlying heart disease. What is it, in this age of life-saving antibiotics, hormonal therapy, surgeries and other seemingly miraculous medical therapies that causes so many individuals to seek therapies outside of conventional medicine? Conventional medicine may be at its best when treating acute crises, but for the treatment of chronic problems it may fall short of offering either cure or healing, leading patients to seek out systems of treatment that they perceive as addressing the causes of their problem, not just the symptoms.
    [Show full text]
  • The Prevalence of and Attitudes Toward Oligomenorrhea and Amenorrhea in Division I Female Athletes
    POPULATION-SPECIFIC CONCERNS The Prevalence of and Attitudes Toward Oligomenorrhea and Amenorrhea in Division I Female Athletes Karen Myrick, DNP, APRN, FNP-BC, Richard Feinn, PhD, and Meaghan Harkins, MS, BSN, RN • Quinnipiac University Research has demonstrated that amenor- hormone and follicle-stimulating hormone rhea and oligomenorrhea may be common shut down stimulation to the ovary, ceasing occurrences among female athletes.1 Due production of estradiol.2 to normalization of menstrual dysfunction The effect of oral contraceptives on the within the sport environment, amenorrhea menstrual cycle include ovulation inhibi- and oligomenorrhea tion, changes in cervical mucus, thinning may be underreported. of the uterine endometrium, and motility Key PointsPoints There are many underly- and secretion in the fallopian tubes, which Lean sport athletes are more likely to per- ing causes of menstrual decrease the likelihood of conception and 3 ceive missed menstrual cycles as normal. dysfunction. However, implantation. Oral contraceptives contain a a similar hypothalamic combination of estrogen and progesterone, Menstrual dysfunction is one prong of the amenorrhea profile is or progesterone only; thus, oral contracep- female athlete triad. frequently seen in ath- tives do not stop the production of estrogen. letes, and hypothalamic Menstrual dysfunction is one prong of the Menstrual dysfunction is often associated dysfunction is com- female athlete triad (triad). The triad is a with musculoskeletal and endothelial monly the root of ath- syndrome of linking low energy availability compromise. lete’s menstrual abnor- (EA) with or without disordered eating, men- malities.2 The common strual disturbances, and low bone mineral Education and awareness of the accultur- hormone pattern for density, across a continuum.
    [Show full text]
  • Infertility Update
    Infertility Update George R Attia, M.D Director of IVF Program University of Texas Southwestern Medical Center at Dallas Infertility • Inability to conceive after one year of adequate unprotected intercourse (six months if the woman is over age 35) Time Required for Conception in Couples Who Will Attain Pregnancy 100 93 95 90 85 80 72 70 nt 57 60 na g 45 e 50 r P 40 % 30 25 20 10 0 1 month 2 months 3 months 6 months 1 Year 2 Year 3 ear 7% 3% 35% Male Factor 20% Tubal Factor Ov dysfunction Unexplained Others 35% 10% 10% 40% Anovulatory Tubal & Pelvic Unusual factors Unexplained 40% • Anovulation • Tubal Factor • Male • Pelvic Factor (Endometriosis, adhesion) • Unexplained • Uterine/cervical (fibroid) 10% PCOS Others 90% Ovulation • History •BBT • LH kits • Mid luteal phase Progesterone (cycle length –7) • Ultrasound • EMB (day 21-26) • Anovulation • Tubal / Pelvic Factor • Male • Unexplained • Uterine/cervical (fibroid) Tubal & Pelvic Factors • Tubal disease, PID • Tubal surgery • Pelvic adhesions • Endometriosis Tubal Factor • Tubal infertility after PID (12%, 24%, 50%) • One-half of patients who found to have tubal damage and/or pelvic adhesion have no history of antecedent disease Tubal Factor • Hysterosalpingography • Hysteroscopy / laparoscopy • Falloscopy • Anovulation • Tubal Factor • Male • Unexplained • Uterine/cervical (fibroid) Male Factor Infertility • Anatomic defects (hypospadias, Retrograde ejac.) • Genetics Causes • Trauma • Infection • Endocrine disorders •Varicocele Male Factor Infertility • Vol. > 2 ml, Conc. > 20x106,
    [Show full text]
  • Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium
    Published OnlineFirst November 15, 2017; DOI: 10.1158/1055-9965.EPI-17-0655 Research Article Cancer Epidemiology, Biomarkers Polycystic Ovary Syndrome, Oligomenorrhea, and & Prevention Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium Holly R. Harris1, Ana Babic2, Penelope M. Webb3,4, Christina M. Nagle3, Susan J. Jordan3,5, on behalf of the Australian Ovarian Cancer Study Group4; Harvey A. Risch6, Mary Anne Rossing1,7, Jennifer A. Doherty8, Marc T.Goodman9,10, Francesmary Modugno11, Roberta B. Ness12, Kirsten B. Moysich13, Susanne K. Kjær14,15, Estrid Høgdall14,16, Allan Jensen14, Joellen M. Schildkraut17, Andrew Berchuck18, Daniel W. Cramer19,20, Elisa V. Bandera21, Nicolas Wentzensen22, Joanne Kotsopoulos23, Steven A. Narod23, † Catherine M. Phelan24, , John R. McLaughlin25, Hoda Anton-Culver26, Argyrios Ziogas26, Celeste L. Pearce27,28, Anna H. Wu28, and Kathryn L. Terry19,20, on behalf of the Ovarian Cancer Association Consortium Abstract Background: Polycystic ovary syndrome (PCOS), and one of its cancer was also observed among women who reported irregular distinguishing characteristics, oligomenorrhea, have both been menstrual cycles compared with women with regular cycles (OR ¼ associated with ovarian cancer risk in some but not all studies. 0.83; 95% CI ¼ 0.76–0.89). No significant association was However, these associations have been rarely examined by observed between self-reported PCOS and invasive ovarian cancer ovarian cancer histotypes, which may explain the lack of clear risk (OR ¼ 0.87; 95% CI ¼ 0.65–1.15). There was a decreased risk associations reported in previous studies. of all individual invasive histotypes for women with menstrual Methods: We analyzed data from 14 case–control studies cycle length >35 days, but no association with serous borderline including 16,594 women with invasive ovarian cancer (n ¼ tumors (Pheterogeneity ¼ 0.006).
    [Show full text]
  • Current Evaluation of Amenorrhea
    Current evaluation of amenorrhea The Practice Committee of the American Society for Reproductive Medicine Birmingham, Alabama Amenorrhea is the absence or abnormal cessation of the menses. Primary and secondary amenorrhea describe the occurrence of amenorrhea before and after menarche, respectively. (Fertil Steril௡ 2006;86(Suppl 4):S148–55. © 2006 by American Society for Reproductive Medicine.) Amenorrhea is the absence or abnormal cessation of the menses complaint. The sexual ambiguity or virilization should be (1). Primary and secondary amenorrhea describe the occurrence evaluated as separate disorders, mindful that amenorrhea is of amenorrhea before and after menarche, respectively. The an important component of their presentation (9). majority of the causes of primary and secondary amenorrhea are similar. Timing of the evaluation of primary amenorrhea EVALUATION OF THE PATIENT recognizes the trend to earlier age at menarche and is therefore History, physical examination, and estimation of follicle indicated when there has been a failure to menstruate by age 15 stimulating hormone (FSH), thyroid stimulating hormone in the presence of normal secondary sexual development (two (TSH), and prolactin will identify the most common causes standard deviations above the mean of 13 years), or within five of amenorrhea (Fig. 1). The presence of breast development years after breast development if that occurs before age 10 (2). means there has been previous estrogen action. Excessive Failure to initiate breast development by age 13 (two standard testosterone secretion is suggested most often by hirsutism deviations above the mean of 10 years) also requires investiga- and rarely by increased muscle mass or other signs of viril- tion (2).
    [Show full text]
  • Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) Revised Glossary on ART Terminology, 2009†
    Human Reproduction, Vol.24, No.11 pp. 2683–2687, 2009 Advanced Access publication on October 4, 2009 doi:10.1093/humrep/dep343 SIMULTANEOUS PUBLICATION Infertility The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) Revised Glossary on ART Terminology, 2009† F. Zegers-Hochschild1,9, G.D. Adamson2, J. de Mouzon3, O. Ishihara4, R. Mansour5, K. Nygren6, E. Sullivan7, and S. van der Poel8 on behalf of ICMART and WHO 1Unit of Reproductive Medicine, Clinicas las Condes, Santiago, Chile 2Fertility Physicians of Northern California, Palo Alto and San Jose, California, USA 3INSERM U822, Hoˆpital de Biceˆtre, Le Kremlin Biceˆtre Cedex, Paris, France 4Saitama Medical University Hospital, Moroyama, Saitana 350-0495, JAPAN 53 Rd 161 Maadi, Cairo 11431, Egypt 6IVF Unit, Sophiahemmet Hospital, Stockholm, Sweden 7Perinatal and Reproductive Epidemiology and Research Unit, School Women’s and Children’s Health, University of New South Wales, Sydney, Australia 8Department of Reproductive Health and Research, and the Special Program of Research, Development and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland 9Correspondence address: Unit of Reproductive Medicine, Clinica las Condes, Lo Fontecilla, 441, Santiago, Chile. Fax: 56-2-6108167, E-mail: fzegers@clc.cl background: Many definitions used in medically assisted reproduction (MAR) vary in different settings, making it difficult to standardize and compare procedures in different countries and regions. With the expansion of infertility interventions worldwide, including lower resource settings, the importance and value of a common nomenclature is critical. The objective is to develop an internationally accepted and continually updated set of definitions, which would be utilized to standardize and harmonize international data collection, and to assist in monitoring the availability, efficacy, and safety of assisted reproductive technology (ART) being practiced worldwide.
    [Show full text]
  • Diagnostic Evaluation of the Infertile Female: a Committee Opinion
    Diagnostic evaluation of the infertile female: a committee opinion Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Diagnostic evaluation for infertility in women should be conducted in a systematic, expeditious, and cost-effective manner to identify all relevant factors with initial emphasis on the least invasive methods for detection of the most common causes of infertility. The purpose of this committee opinion is to provide a critical review of the current methods and procedures for the evaluation of the infertile female, and it replaces the document of the same name, last published in 2012 (Fertil Steril 2012;98:302–7). (Fertil SterilÒ 2015;103:e44–50. Ó2015 by American Society for Reproductive Medicine.) Key Words: Infertility, oocyte, ovarian reserve, unexplained, conception Use your smartphone to scan this QR code Earn online CME credit related to this document at www.asrm.org/elearn and connect to the discussion forum for Discuss: You can discuss this article with its authors and with other ASRM members at http:// this article now.* fertstertforum.com/asrmpraccom-diagnostic-evaluation-infertile-female/ * Download a free QR code scanner by searching for “QR scanner” in your smartphone’s app store or app marketplace. diagnostic evaluation for infer- of the male partner are described in a Pregnancy history (gravidity, parity, tility is indicated for women separate document (5). Women who pregnancy outcome, and associated A who fail to achieve a successful are planning to attempt pregnancy via complications) pregnancy after 12 months or more of insemination with sperm from a known Previous methods of contraception regular unprotected intercourse (1).
    [Show full text]
  • Changes Before the Change1.06 MB
    Changes before the Change Perimenopausal bleeding Although some women may abruptly stop having periods leading up to the menopause, many will notice changes in patterns and irregular bleeding. Whilst this can be a natural phase in your life, it may be important to see your healthcare professional to rule out other health conditions if other worrying symptoms occur. For further information visit www.imsociety.org International Menopause Society, PO Box 751, Cornwall TR2 4WD Tel: +44 01726 884 221 Email: leetomkinsims@btinternet.com Changes before the Change Perimenopausal bleeding What is menopause? Strictly defined, menopause is the last menstrual period. It defines the end of a woman’s reproductive years as her ovaries run out of eggs. Now the cells in the ovary are producing less and less hormones and menstruation eventually stops. What is perimenopause? On average, the perimenopause can last one to four years. It is the period of time preceding and just after the menopause itself. In industrialized countries, the median age of onset of the perimenopause is 47.5 years. However, this is highly variable. It is important to note that menopause itself occurs on average at age 51 and can occur between ages 45 to 55. Actually the time to one’s last menstrual period is defined as the perimenopausal transition. Often the transition can even last longer, five to seven years. What hormonal changes occur during the perimenopause? When a woman cycles, she produces two major hormones, Estrogen and Progesterone. Both of these hormones come from the cells surrounding the eggs. Estrogen is needed for the uterine lining to grow and Progesterone is produced when the egg is released at ovulation.
    [Show full text]
  • Abnormal Uterine Bleeding: a Management Algorithm
    J Am Board Fam Med: first published as 10.3122/jabfm.19.6.590 on 7 November 2006. Downloaded from EVIDENCED-BASED CLINICAL MEDICINE Abnormal Uterine Bleeding: A Management Algorithm John W. Ely, MD, MSPH, Colleen M. Kennedy, MD, MS, Elizabeth C. Clark, MD, MPH, and Noelle C. Bowdler, MD Abnormal uterine bleeding is a common problem, and its management can be complex. Because of this complexity, concise guidelines have been difficult to develop. We constructed a concise but comprehen- sive algorithm for the management of abnormal uterine bleeding between menarche and menopause that was based on a systematic review of the literature as well as the actual management of patients seen in a gynecology clinic. We started by drafting an algorithm that was based on a MEDLINE search for rel- evant reviews and original research. We compared this algorithm to the actual care provided to a ran- dom sample of 100 women with abnormal bleeding who were seen in a university gynecology clinic. Discrepancies between the algorithm and actual care were discussed during audiotaped meetings among the 4 investigators (2 family physicians and 2 gynecologists). The audiotapes were used to revise the algorithm. After 3 iterations of this process (total of 300 patients), we agreed on a final algorithm that generally followed the practices we observed, while maintaining consistency with the evidence. In clinic, the gynecologists categorized the patient’s bleeding pattern into 1 of 4 types: irregular bleeding, heavy but regular bleeding (menorrhagia), severe acute bleeding, and abnormal bleeding associated with a contraceptive method. Subsequent management involved both diagnostic and treatment interven- tions, which often occurred simultaneously.
    [Show full text]
  • Too Much, Too Little, Too Late: Abnormal Uterine Bleeding
    Too much, too little, too late: Abnormal uterine bleeding Jody Steinauer, MD, MAS July, 2015 The Questions • Too much (& too early or too late) – Differential and approach to work‐up – Does she need an endometrial biopsy (EMB)? – Does she need an ultrasound? – How do I stop peri‐menopausal bleeding? – Isn’t it due to the fibroids? • Too fast: She’s hemorrhaging—what do I do? • Too little: A quick review of amenorrhea Case 1 A 46 yo G3P2T1 reports her periods have become 1. What term describes increasingly irregular and heavy her symptoms? over the last 6‐8 months. 2. Physiologically, what Sometimes they come 2 times causes this type of per month and sometimes there bleeding pattern? are 2 months between. LMP 2 3. What is the months ago. She bleeds 10 days differential? with clots and frequently bleeds through pads to her clothes. She occasionally has hot flashes. She also has diabetes and is obese. Q1: In addition to a urine pregnancy test and TSH, which of the following is the most appropriate test to obtain at this time? 1. FSH 2. Testosterone & DHEAS 3. Serum beta‐HCG 4. Transvaginal Ultrasound (TVUS) 5. Endometrial Biopsy (EMB) Terminology: What is abnormal? • Normal: Cycle= 28 days +‐ 7 d (21‐35); Length=2‐7 days; Heaviness=self‐defined • Too little bleeding: amenorrhea or oligomenorrhea • Too much bleeding: Menorrhagia (regular timing but heavy (according to patient) OR long flow (>7 days) • Irregular bleeding: Metrorrhagia, intermenstrual or post‐ coital bleeding • Irregular and Excessive: Menometrorrhagia • Preferred term for non‐pregnant bleeding issues= Abnormal Uterine Bleeding (AUB) – Avoid “DUB” ‐ dysfunctional uterine bleeding.
    [Show full text]
  • Oligo-Anovulation Is Not a Rarer Feature in Women with Documented Endometriosis
    Oligo-anovulation is not a rarer feature in women with documented endometriosis Pietro Santulli, M.D., Ph.D.,a,b Chloe Tran, M.D.,a Vanessa Gayet, M.D.,a Mathilde Bourdon, M.D.,a,b Chloe Maignien, M.D.,a Louis Marcellin, M.D.,a,b Khaled Pocate-Cheriet, M.D.,b Charles Chapron, M.D.,a,b and Dominique de Ziegler, M.D.a a Department of Gynaecology Obstetrics II and Reproductive Medicine, Assistance Publique-Hopitaux^ de Paris (AP-HP), Hopital^ Universitaire Paris Centre, Centre Hospitalier Universitaire (CHU) Cochin, Universite Paris Descartes, Sorbonne Paris Cite; and b Department of Development, Reproduction and Cancer, Institut Cochin, INSERM U1016, Universite Paris Descartes, Sorbonne Paris Cite, Paris, France Objective: To study the prevalence of oligo-anovulation in women suffering from endometriosis compared to that of women without endometriosis. Design: A single-center, cross-sectional study. Setting: University hospital-based research center. Patient (s): We included 354 women with histologically proven endometriosis and 474 women in whom endometriosis was surgically ruled out between 2004 and 2016. Intervention: None. Main Outcome Measure(s): Frequency of oligo-anovulation in women with endometriosis as compared to that prevailing in the disease-free reference group. Results: There was no difference in the rate of oligo-anovulation between women with endometriosis (15.0%) and the reference group (11.2%). Regarding the endometriosis phenotype, oligo-anovulation was reported in 12 (18.2%) superficial peritoneal endometriosis, 12 (10.6%) ovarian endometrioma, and 29 (16.6%) deep infiltrating endometriosis. Conclusion(s): Endometriosis should not be discounted in women presenting with oligo-anovulation.
    [Show full text]
  • Age and Fertility: a Guide for Patients
    Age and Fertility A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction of the Patient Education Committee and the Publications Committee. No portion herein may be reproduced in any form without written permission. This booklet is in no way intended to replace, dictate or fully define evaluation and treatment by a qualified physician. It is intended solely as an aid for patients seeking general information on issues in reproductive medicine. Copyright © 2012 by the American Society for Reproductive Medicine AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE Age and Fertility A Guide for Patients Revised 2012 A glossary of italicized words is located at the end of this booklet. INTRODUCTION Fertility changes with age. Both males and females become fertile in their teens following puberty. For girls, the beginning of their reproductive years is marked by the onset of ovulation and menstruation. It is commonly understood that after menopause women are no longer able to become pregnant. Generally, reproductive potential decreases as women get older, and fertility can be expected to end 5 to 10 years before menopause. In today’s society, age-related infertility is becoming more common because, for a variety of reasons, many women wait until their 30s to begin their families. Even though women today are healthier and taking better care of themselves than ever before, improved health in later life does not offset the natural age-related decline in fertility. It is important to understand that fertility declines as a woman ages due to the normal age- related decrease in the number of eggs that remain in her ovaries.
    [Show full text]